Effects of heparin on temporal microRNA profiles.
作者信息
Mayr Manuel, Lee Regent, Kaudewitz Dorothee, Zampetaki Anna, Channon Keith M
出版信息
J Am Coll Cardiol. 2014 Mar 11;63(9):940-1. doi: 10.1016/j.jacc.2013.07.118. Epub 2013 Dec 4.
Abstract
摘要
相似文献
1
Effects of heparin on temporal microRNA profiles.
J Am Coll Cardiol. 2014 Mar 11;63(9):940-1. doi: 10.1016/j.jacc.2013.07.118. Epub 2013 Dec 4.
2
Reply: effects of heparin on temporal microRNA profiles.
J Am Coll Cardiol. 2014 Mar 11;63(9):941-2. doi: 10.1016/j.jacc.2013.09.077. Epub 2013 Dec 4.
3
MicroRNA and myocardial infarction: a mystery turning into glory?
J Am Coll Cardiol. 2013 Sep 10;62(11):999-1001. doi: 10.1016/j.jacc.2013.03.084. Epub 2013 Jun 7.
4
Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy.
J Am Coll Cardiol. 2013 Sep 10;62(11):992-8. doi: 10.1016/j.jacc.2013.05.025. Epub 2013 Jun 7.
5
When do we monitor for the effects of a "therapeutic" myocardial infarction?
Prog Cardiovasc Nurs. 2002 Summer;17(3):152-4. doi: 10.1111/j.0889-7204.2002.01539.x.
6
Acute myocardial infarction occurring after hypertrophic obstructive cardiomyopathy with paroxysmal atrial fibrillation: a case report.
J Int Med Res. 2022 Oct;50(10):3000605221133702. doi: 10.1177/03000605221133702.
7
Disappearance of septal Q waves following percutaneous transluminal septal myocardial ablation for obstructive hypertrophic cardiomyopathy.
Am J Cardiol. 2003 Feb 15;91(4):515-6. doi: 10.1016/s0002-9149(02)03293-9.
8
Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy.
Clin Transl Med. 2021 Jul;11(7):e435. doi: 10.1002/ctm2.435.
9
In percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy, it is not the speed of intracoronary alcohol injection but the amount of alcohol injected that determines the resultant infarct size.
Circulation. 2004 Jul 20;110(3):e23; author reply e23. doi: 10.1161/01.CIR.0000135537.69990.0F.
10
Septal myectomy for hypertrophic obstructive cardiomyopathy: coil, boil and the role of rescue surgery.
Eur J Cardiothorac Surg. 2009 Jul;36(1):210-1. doi: 10.1016/j.ejcts.2009.03.033. Epub 2009 May 1.
引用本文的文献
1
Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129.
Cardiovasc Res. 2022 Dec 29;118(16):3183-3197. doi: 10.1093/cvr/cvab327.
2
A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy.
Heart Fail Rev. 2022 Jan;27(1):281-294. doi: 10.1007/s10741-021-10084-y. Epub 2021 Mar 3.
3
MiR-223 levels predicting perioperative bleeding in off-pump coronary artery bypass grafting.
Ann Transl Med. 2020 Nov;8(21):1341. doi: 10.21037/atm-20-2022b.
4
Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury.
Circ Res. 2019 Jul 19;125(3):328-340. doi: 10.1161/CIRCRESAHA.119.314937. Epub 2019 Jun 4.
5
Optimisation of laboratory methods for whole transcriptomic RNA analyses in human left ventricular biopsies and blood samples of clinical relevance.
PLoS One. 2019 Mar 14;14(3):e0213685. doi: 10.1371/journal.pone.0213685. eCollection 2019.
6
Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease.
Biomed Res Int. 2016;2016:2901938. doi: 10.1155/2016/2901938. Epub 2016 Sep 20.
7
Heparinase treatment of heparin-contaminated plasma from coronary artery bypass grafting patients enables reliable quantification of microRNAs.
Biomol Detect Quantif. 2016 Apr 8;8:9-14. doi: 10.1016/j.bdq.2016.03.001. eCollection 2016 Jun.
8
MicroRNA Biomarkers for Coronary Artery Disease?
Curr Atheroscler Rep. 2015 Dec;17(12):70. doi: 10.1007/s11883-015-0548-z.
9
MicroRNAs as clinical biomarkers?
Front Genet. 2015 Jul 14;6:240. doi: 10.3389/fgene.2015.00240. eCollection 2015.
10
Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device.
Eur J Heart Fail. 2014 Aug;16(8):871-9. doi: 10.1002/ejhf.116. Epub 2014 Jun 24.
本文引用的文献
1
Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease.
Thromb Haemost. 2013 Sep;110(3):609-15. doi: 10.1160/TH13-05-0368. Epub 2013 Jun 27.
2
Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy.
J Am Coll Cardiol. 2013 Sep 10;62(11):992-8. doi: 10.1016/j.jacc.2013.05.025. Epub 2013 Jun 7.
3
MicroRNA and myocardial infarction: a mystery turning into glory?
J Am Coll Cardiol. 2013 Sep 10;62(11):999-1001. doi: 10.1016/j.jacc.2013.03.084. Epub 2013 Jun 7.
4
Heparin selectively affects the quantification of microRNAs in human blood samples.
Clin Chem. 2013 Jul;59(7):1125-7. doi: 10.1373/clinchem.2012.199505. Epub 2013 Apr 23.
5
Circulating microRNAs as novel biomarkers for platelet activation.
Circ Res. 2013 Feb 15;112(4):595-600. doi: 10.1161/CIRCRESAHA.111.300539. Epub 2013 Jan 2.
6
Prospective study on circulating MicroRNAs and risk of myocardial infarction.
J Am Coll Cardiol. 2012 Jul 24;60(4):290-9. doi: 10.1016/j.jacc.2012.03.056.
7
Analytical challenges and technical limitations in assessing circulating miRNAs.
Thromb Haemost. 2012 Oct;108(4):592-8. doi: 10.1160/TH12-02-0097. Epub 2012 May 25.
8
Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation.
Eur Heart J. 2011 May;32(9):1059-64. doi: 10.1093/eurheartj/ehr013. Epub 2011 Mar 29.
Zotero 插件